Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash from Financing Activities for 6 consecutive years, with $112.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 18532.61% to $112.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $113.3 million through Dec 2025, down 66.41% year-over-year, with the annual reading at $113.0 million for FY2025, 66.51% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $112.0 million at 4D Molecular Therapeutics, up from $116000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $318.8 million in Q1 2024, with the low at -$847000.0 in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $40.4 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 117.74% in 2021, then soared 261138.0% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $116.1 million in 2021, then plummeted by 98.24% to $2.0 million in 2022, then surged by 132.75% to $4.8 million in 2023, then plummeted by 87.38% to $601000.0 in 2024, then surged by 18532.61% to $112.0 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $112.0 million, $116000.0, and $601000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.